Marimon Jose Maria, Ardanuy Carmen
Biodonostia, Infectious Diseases Area, Respiratory Infection and Antimicrobial Resistance Group, Osakidetza Basque Health Service, Donostialdea Integrated Health Organisation, Microbiology Department, San Sebastian, Spain.
Microbiology Department. Hospital Universitari Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Spain; Research Network for Respiratory Diseases (CIBERES), ISCIII, Madrid, Spain; Department of Pathology and Experimental Therapeutics, School of Medicine, University of Barcelona, Barcelona, Spain.
Enferm Infecc Microbiol Clin (Engl Ed). 2021 Mar;39(3):142-150. doi: 10.1016/j.eimc.2020.02.016. Epub 2020 Mar 27.
In Spain, the use of pneumococcal conjugate vaccines (PCVs) has led to a decrease in the incidence of vaccine serotypes causing invasive and non-invasive disease in vaccinated and unvaccinated children and adults. Further, the coverage of most of the resistant serotypes by vaccines resulted in an overall decline in antibiotic resistance. As an undesirable effect, there was an increase in the non-vaccine serotypes causing infection, especially serotypes 1, 7F and 19A after PCV7 and serotype 8 after PCV13 approval, this making the beneficial effect of vaccination less apparent. The inclusion of PCVs in childhood vaccination schedules, its approval for use in healthy adults and the increasing number of serotypes covered by the vaccines in development are strong strategies in the fight against pneumococcal disease. Nonetheless, the epidemiology of Streptococcus pneumoniae infections must be still under surveillance to detect new changes, given the high capacity for recombination and adaptability of this always-surprising microorganism.
在西班牙,使用肺炎球菌结合疫苗(PCV)已导致在接种和未接种疫苗的儿童及成人中,引起侵袭性和非侵袭性疾病的疫苗血清型发病率下降。此外,疫苗对大多数耐药血清型的覆盖导致抗生素耐药性总体下降。作为一种不良影响,引起感染的非疫苗血清型有所增加,尤其是在PCV7之后的1、7F和19A血清型以及PCV13获批后的8血清型,这使得疫苗接种的有益效果不那么明显。将PCV纳入儿童疫苗接种计划、其在健康成人中的使用获批以及正在研发的疫苗所涵盖血清型数量的增加,都是抗击肺炎球菌疾病的有力策略。尽管如此,鉴于肺炎链球菌这种总是令人惊讶的微生物具有高重组能力和适应性,仍必须对其感染的流行病学进行监测,以发现新的变化。